Results 101 to 110 of about 7,099 (210)
, 2022 Abstract Background/purpose: Clinical relapse occurred majorly within the first six months after stopping tenofovir disoproxil fumarate (TDF) in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. However, the incidence and relapse pattern in patients stopping Tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir ...
CH Chen +7 more
openaire +1 more source
Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV [PDF]
, 2021 A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine,
Kathuria, Priya
core +1 more source
Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? [PDF]
, 2016 The international community has committed to ending the epidemics of HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030, and this bold stance deserves universal support.
Harries, Anthony D +6 more
core +2 more sources
Clinical and Translational Science, Volume 19, Issue 5, May 2026.
Inès Ben Ghezala, Marc Bardou
wiley +1 more source
DETERMINANTS OF ANTI-RETROVIRAL THERAPY DRUG-RELATED TOXICITIES IN HIV POSITIVE PATIENTS [PDF]
Antiretroviral therapy (ART) drugs have increasingly been shown to contribute significantly to the morbidity of HIV positive patients exposed to them. This is more so with increasing survival of HIV patients since the introduction of ART.
Danjuma, MI, Danjuma, MI
core +1 more source
Drug Design, Development and Therapy, 2017 Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
MDM Policy & PracticeBackground. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan +6 more
doaj +1 more source
PLoS ONE, 2019 BackgroundBecause tenofovir alafenamide (TAF) leads to significantly lower plasma tenofovir concentrations than tenofovir disoproxil fumarate (TDF) and is a stronger substrate for P-glycoprotein (P-gp) than TDF, TAF could lead to decreased central ...
Linn Hermansson +9 more
doaj +1 more source
Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]
, 2019 Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre +3 more
core +1 more source
Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]
, 2017 The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J +3 more
core +2 more sources